Other News To Note
Monday, July 29, 2013
Furiex Pharmaceuticals Inc., of Morrisville, N.C., confirmed that Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, got a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Vipidia (alogliptin), and fixed-dose combinations Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone) for the treatment of Type II diabetes patients who are uncontrolled on existing therapies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.